Comparison of Hemanext ONE® System and Conventional Red Blood Cell Transfusion
NCT: NCT06685848 · ACTIVE_NOT_RECRUITING
Brief Summary
The overall objective of this study is to collect preliminary effectiveness and safety data on the transfusion of hypoxic RBCs, manufactured with the Hemanext ONE device, in patients with hematological malignancies. The Hemanext ONE device received CE mark in April 2021 and marketing authorization through the FDA De Novo process in September 2023.
Frequently Asked Questions
What is Comparison of Hemanext ONE® System and Conventional Red Blood Cell Transfusion?
Comparison of Hemanext ONE® System and Conventional Red Blood Cell Transfusion is a clinical trial registered under NCT06685848. Current status: ACTIVE_NOT_RECRUITING.
What is the status of NCT06685848?
The current status of NCT06685848 (Comparison of Hemanext ONE® System and Conventional Red Blood Cell Transfusion) is: ACTIVE_NOT_RECRUITING.
When did Comparison of Hemanext ONE® System and Conventional Red Blood Cell Transfusion start?
Comparison of Hemanext ONE® System and Conventional Red Blood Cell Transfusion started on 2024-11-29.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.